Aurobindo Pharma Limited on June 3 inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing facilities, in Borapatla, Hyderabad. The facility was launched in the presence of Telangana ministers Shri D. Sridhar Babu and Shri Damodar Raja Narasimha.
TheraNym Biologics, a subsidiary of Aurobindo Pharma, is equipped with 15 KL bioreactors, advanced downstream processing suites, aseptic fill-finish capabilities, and quality control laboratories. The facility has been designed to meet international regulatory standards and will support supply chains for both domestic and export markets, subject to applicable approvals and customer requirements.
MSD has joined TheraNym as its anchor customer. Dr. Dave Maraldo, MSD Executive Vice President and President of the MSD Manufacturing Division, said the partnership is focused on strengthening global access to critical biologic medicines. TheraNym adds meaningful capacity and capability to the MSD supply chain, helping enable compliant and reliable supply of products to patients, he said.
Dr. Satakarni Makkapati, CEO Biologics and Director of Aurobindo Pharma Limited, said the facility is positioned to serve the supply chains of leading global pharmaceutical companies worldwide. Nithyananda Reddy, Vice Chairman and MD of Aurobindo Pharma, said the company is prioritizing biologics contract manufacturing as a core differentiator, building on its biosimilars foray through CuraTeQ.
Prior to the inauguration, the Directors of Aurobindo Pharma and senior leadership of MSD met Telangana Chief Minister Shri Anumula Revanth Reddy to brief him on the project. The government's Telangana Life Sciences Policy and investment facilitation have supported the development, the company said.
Aurobindo Pharma holds a global footprint spanning over 150 countries and is listed on the NSE and BSE. The company operates across generics, injectables, and complex biologics.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.